Rss Top Picks FeedRss Daily Feed| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
| There are 15 registered members and 95 guests viewing the site. | Follow us on Twitter | Rss Top Picks Feed | Rss Daily Feed |
|
| TOP PICK | 44.550 | Barry Schwartz | Likes companies that have low valuations, great history of rising dividends and potential for double digit earnings growth in the coming year. Thinks it will earn $5.50 in 2012. Trading at 8X earnings. Raised its dividends 12 years in a row. Thinks they will be very active looking to acquire big quality branded orphan drugs. | 2012-01-16 | |
| STRONG BUY | 40.660 | Barry Schwartz | Not sure why it has been beaten up so much but may have to do with a recent acquisition and concerns on how they are going to integrate it. 3 of the worst performing stocks this year are financials, pharmaceuticals and technology. Very, very cheap valuation. Raised its dividends 10 years in a row. | 2011-12-12 | |
| SELL | 35.260 | Norman Levine | Really likes the generic drug business but he sold it because it is not a pure play generic. They also have the leading MS drug under patent. It will go off patent in the next year or so, so they also have a patent cliff. It is finally getting some real competition in the MS area. He decided to move on. | 2011-09-23 | |
| DON'T BUY | 38.330 | Christine Poole | The largest generic drug producer but also have a branded division. There is concern that there will be increasing competition. As well, expect there will be increasing pressure for any industry that is being reimbursed by governments, especially the US. As the market improves, this stock should lift from here but longer-term, she wouldn't be a buyer. | 2011-09-14 | |
| Comment | 38.330 | Barry Schwartz | Generic drugs plus one big branded drug that is going to face a lot of competition. Very attractive valuation. Not too excited about their acquisition of Cephalon. Not significantly adding to his holdings at this price. If you think it is going to recover, this is a great price. | 2011-09-14 | |
| STRONG BUY | 40.530 | Karl Berger | Generic drug industry – governments should have preference for generic drugs. They will continue to grow. They had patent challenges from an MS drug they make. Should come to court in the fall. Market will eventually realize there is more value. Worth looking at. He was thinking of recommending it as a top pick today. | 2011-08-30 | |
| DON'T BUY | 39.420 | Norman Levine | Recently sold his holdings. Liked the generic drug business. This one is not exclusively generic. Their biggest product that contributes the most to earnings is a multiple sclerosis drug and this will be coming off patent in the next couple of years. A lot of competition coming out on this drug. | 2011-08-26 | |
| DON'T BUY | 36.340 | Hap (Robert) Sneddon FCSI | Healthcare in the US had a pretty good run followed by a precipitous drop. There are probably better names. | 2011-08-08 | |
| Comment | 48.430 | Lorne Steinberg | Making all kinds of generic drugs and also do their own research/development and doing non-generic drugs as well. Not cheap enough for him to buy. | 2011-07-14 | |
| BUY | 48.990 | Barry Schwartz | Generic drugs and its prospects are very strong. A lot of value under $50 a share. Trading at less than 10X earnings. Just made a big acquisition. Doing all the right things. | 2011-07-06 | |
| PAST TOP PICK | 49.140 | Charles Lannon | (A Top Pick Apr 29/10. Down 13.9%.) Still likes and is still buying. Suffered from headline risk on one of its drugs. | 2011-06-13 | |
| BUY | 46.460 | Barry Schwartz | Lots of exciting news in the last 3 weeks. They have one blockbuster drug for MS. Another competitor came out with good results on the competing new drug. Cephalon is a small acquisition for them, but has 4 strong branded drugs. US Health care stocks have been beaten down too much and there are good entry points on a lot of names. Started buying TEVA about a month ago. | 2011-05-03 | |
| DON'T BUY | 47.270 | John Zechner | Had great growth over the last number of years. The big news was their outbidding Valeant (VRX-T) for Cephalon (CEPH-Q). Didn’t have to pay up much for this. This should keep growth going for them. He is not big on pharmaceuticals and sees no need to chase it at this price. | 2011-05-02 | |
| DON'T BUY | 47.270 | Christine Poole | Buying Cephalon (CEPH-Q), which diversifies their revenue source from their branded drugs. Have a very successful branded drug for treating multiple cirrhosis but there is potential competition coming in the next couple of years. Trading at a very low multiple, below 10X. She prefers more diversified health care names. | 2011-05-02 | |
| Comment | 48.670 | Peter Brieger | Very big in the generic market. First class company. 1.5% yield. Would prefer Johnson & Johnson (JNJ-N). | 2011-04-19 | |
| BUY | 49.900 | Richard Fogler | Largest generic pharmaceutical company globally. Having a lot of trouble getting around $50. Great company and is not expensive. Earnings will come in around $5, trading at 10X earnings. Has a terrific outlook. | 2011-04-14 | |
| BUY | 48.980 | Barry Schwartz | Most of their drugs are generic. #1 drug is a blockbuster for MS but competition came out with a drug that had good results. Only trades at 10X earnings and has fast growth. Missed its last quarter giving an opportunity to buy at a 20% discount. With an 8 to 12 month time horizon you should do well. | 2011-04-11 | |
| DON'T BUY | 50.790 | David Burrows | Generic drugs. Has had great success over time taking drugs that are coming off patent and reformulating them. Have had a couple of hiccups in the last year or so in getting new drugs approved. Have a couple of non-generic drugs that are now being challenged by generics. Have missed a couple of estimates in a row. Prefers Perrigo (PRGO-Q). | 2011-04-07 | |
| TOP PICK | 49.930 | Barry Schwartz | Forth quarter earnings and guidance were not what the analysts were looking for and the stock dropped. Thinks they will earn about $5/share in 2011. Significant free cash flow, double digit growth, best pipeline of any of the generic manufacturers. Very, very shareholder friendly. 25% discount to its piers. | 2011-03-01 | |
|
| |||||
| Comment | 50.100 | Norman Levine | Sold half his position when it was higher. Really 2 companies. Biggest part is generics. They are the biggest manufacturer globally. A lot of patented drugs will become invalid and they will grow because of it. They are also a pharmaceutical because they have a few drugs. One of them is an MS drug and a large part of their profits. It too is possibly coming up for generic competition, which has held the stock back but this is an opportunity. Probably won’t go any where for a little while. (See Top Picks.) | 2011-02-28 | |
| BUY | 51.040 | Karl Berger | Loves the generic drug theme, which is a theme that will continue over the next couple of years as governments continue to cut health care coasts. Good growth. | 2011-02-11 | |
| BUY | 50.370 | Paul Harris, CFA | Generic pharmaceutical company out of Israel and is the best in that market. Well run. If you have a long-term view, you should own this one. | 2010-11-25 | |
| Comment | 49.940 | Don Reed | Could be some major strengths in generic drugs going forward. | 2010-11-23 | |
| PAST TOP PICK | 50.530 | Laura Wallace | (A Top Pick Nov 26/09. Down 3.11%.) Still likes. | 2010-11-18 | |
| HOLD | 50.560 | Norman Levine | Has owned for quite some time. Likes outlook for generic drug companies. They also have some of the their own drugs. There are competing drugs coming out and could be so-so for them. He sold half a couple of months ago. Likes health care in general: valuations are low and dividends are growing and there will be more demand for health-care in the US. | 2010-11-09 | |
| TOP PICK | 54.260 | Tony Demarin | World leader in generic drug manufacturing. Significant operations in Europe and the US. Made a couple of good acquisitions. Will benefit when other companies drugs come off patent. | 2010-09-15 | |
| BUY | 54.260 | Ara Nalbandian | One of the world's largest generic drug manufacturers. 25% global market share. Expect they can consistently grow earnings in the 10%-12% range. His target would be $55. | 2010-09-15 | |
| TOP PICK | 50.350 | Karl Berger | Primarily a generic drug manufacturer. Market has overreacted with the challenge it is facing with from a competitor on one of its branded drugs. 1.5% yield. | 2010-08-27 | |
| BUY on WEAKNESS | 51.990 | David Driscoll | Leading generic drug manufacturer globally. Good growth profile. Valuations in the $40-$50 range would be decent. Growth rate is in the high mid-teens too low $20's. | 2010-06-24 | |
| DON'T BUY | 52.750 | David Burrows | Global leader with about 60% of revenues from US. Generics have recently under performed because of regulatory changes that are squeezing profitability. Generics will continue to expand market share. Acquisitions can take time for results to show in the numbers. Trading below 200 day moving average. Would prefer to see if trading above $60. | 2010-06-21 | |
| HOLD | 51.300 | Norman Levine | Owns half as much as he used to. Worried about their biggest non-generic product. It’s an MS drug with a lot of controversy. | 2010-06-09 | |
| Comment | 59.180 | David Baskin | Generic drugs are going to thrive. Cost of drugs is killing global governments that pay for them. The solution is generics that typically cost a fraction. He is wary of the entire pharmaceutical industry. | 2010-05-10 | |
| TOP PICK | 58.800 | Karl Berger | Likes the generic space. Expects there will be increasing appetite for governments globally to spend less on health care. Have some very aggressive growth targets for the next 4-5 years. Have been very good at doing acquisitions. | 2010-05-06 | |
| PAST TOP PICK | 60.560 | Norman Levine | (A Top Pick May 6/09. Up 37% excluding dividends.) Largest global generic manufacturer. Made acquisitions that strengthens them geographically. Trend towards generics is going to continue. | 2010-05-05 | |
| TOP PICK | 58.510 | Charles Lannon | Largest manufacturer of generic drugs. Have a pipeline potential of over $100 billion over the next 5 years as patents come off from large pharmaceuticals. Seriously undervalued. | 2010-04-29 | |
| DON'T BUY | 60.920 | Christine Poole | Half business is generic drugs. US health care companies are reporting. New US reform will cause increased rebates to Medicaid. This is primary reason for TEVA coming off along with the group. | 2010-04-26 | |
| Comment | 63.510 | David Driscoll | Generics continue to get wins in terms of shortened time frames as to pharmaceuticals staying on patents. | 2010-04-07 | |
| PAST TOP PICK | 56.180 | Laura Wallace | (A Top Pick Jan 28/09. Up 34.77%.) Buy on weakness. | 2009-12-31 | |
| TOP PICK | 53.160 | Laura Wallace | Dominant generics player globally. Has 25% of the generic market in the US. Expecting some form of health care will pass in the US, which will bring 20-40 million people into the health-care system. Trading at only about 15X earnings. Very strong growth prospects. | 2009-11-26 | |
|
| |||||
| PAST TOP PICK | 52.810 | Norman Levine | (A Top Pick Nov 11/08. Up 24.69%.) Still likes. | 2009-11-16 | |
| BUY | 51.190 | Norman Levine | More and more major drugs are coming off patent over the next few years. Being the biggest they will get the lion’s share. | 2009-10-13 | |
| TOP PICK | 50.750 | Keith Richards | (A Top Pick May 11/09. Up 12.75%.) Has been in a great uptrend for many years. Thinks you will be able to buy this on a pullback within the next 30 days or so. Fundamentals are good on this company. | 2009-09-24 | |
| PAST TOP PICK | 51.160 | Andrew Guy, CFA | (A Top Pick Oct 14/08. Up 23.38%.) World's largest generic drug company. Also have some branded drugs that are doing very well. | 2009-09-04 | |
| Comment | 52.520 | Karl Berger | Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.) | 2009-08-25 | |
| BUY | 52.220 | Norman Levine | World's largest manufacturer of generic drugs. Also has its own patented proprietary drugs. Has grown through acquisitions and by taking advantage of the drugs that are coming off patent. | 2009-08-24 | |
| Comment | 52.820 | Stan Wong | Likes the generic drug space, especially with the new US administration. There are a lot of moves up in estimates, both quarterly and annual. He also likes Mylan (MYL-Q), which has a little bit more growth and probably cheaper on a PE level. | 2009-07-30 | |
| DON'T BUY | 54.250 | Brett Hryb | Once generic stocks have their products in place they can milk it for several years to come. He wouldn't be looking at this right now. | 2009-07-29 | |
| PAST TOP PICK | 49.470 | Norman Levine | (A Top Pick July 21/08. Up 14.55%.) | 2009-07-22 | |
| TOP PICK | 46.430 | Laura Wallace | Has 25% of the US generic drug market. Generics will gain with the government’s new health plans. Trades at about 15X earnings. Long record of successfully increasing earnings and dividends. | 2009-06-23 | |
| BUY | 47.780 | Norman Levine | Largest generic drug manufacturer globally. Grows through patents coming off existing drugs and by making acquisitions. Have also developed a number of drugs on their own. | 2009-06-08 | |
| TOP PICK | 45.150 | Keith Richards | Countries everywhere will be looking at ways of cutting back on drug costs. This is the biggest generic drug company globally. A defensive sector. | 2009-05-11 | |
| TOP PICK | 44.280 | Norman Levine | During the bear market decline, this stock held in like a rock. It's both defensive and growth. Selling at less than half of its 30% growth rate. Hitting on all cylinders. | 2009-05-06 | |
| TOP PICK | 44.530 | Gerald Allaye-Chan | World's largest drug market and will benefit from US push to lower health care costs. Likes it for growth. Likely to see 30% in short term. Biggest risk is the development of new drug candidates. | 2009-04-17 | |
| TOP PICK | 45.150 | Laura Wallace | World’s largest generic manufacturer. With their Barr acquisition they now have 25% of the US generic market and 17% of the total prescription market. This is in an era where it looks like the US administration is moving to a more nationalized health care plan | 2009-04-07 | |
| TOP PICK | 44.320 | Gerald Allaye-Chan | Worlds largest maker of generic drugs. US administration is likely to push forward towards greater use of generics that would give them a $9.2 billion savings over the next 10 years. This company will be a beneficiary. Made an acquisition last year of Barr Pharmaceuticals, which will give them good synergies. | 2009-03-06 | |
| TOP PICK | 43.910 | Laura Wallace | Israeli-based pharmaceutical company. Recently completed an acquisition of US Barr Pharmaceuticals giving them the largest share (25%) of the generic market in the US. US healthcare focus on generics is going to increase. Leader in producing new generics and is able to negotiate better prices for its products. Earnings in 2010 are expected to increase by more than 30%. Small but growing dividend. | 2009-03-04 | |
| PAST TOP PICK | 44.580 | Norman Levine | (A Top Pick Feb 26/02. Down 10.2%.) | 2009-02-27 | |
| TOP PICK | 41.910 | Laura Wallace | Generic drugs. Manufactures more than 25% of the US market. In a move to more universal medicine in the US, generic manufacturers are going to be big beneficiaries. Earnings are likely to increase by 50% in the 2009 to 2012 period. Trading at 15X earnings. | 2009-01-28 | |
| Comment | 41.710 | David Burrows | (Market Call Minute.) Likes this as a company. In the very short run the health care stocks are under performing in the last couple of weeks. If you like pharmaceuticals, this is one that you could purchase. | 2009-01-07 | |
|
| |||||
| DON'T BUY | 42.410 | David Driscoll | Outsource pharmaceutical manufacturer of generic drugs. No barriers to stop others from doing the same kind of business. He prefers Johnson & Johnson (JNJ-N) or Novartis (NVS-N) who specialize in what they do. | 2008-12-12 | |
| BUY | 41.350 | David Burrows | Trading down 5% on a one-year basis and 14 X forward earnings. This would be a more conservative buy then Gilead (GILD-Q). | 2008-12-01 | |
| TOP PICK | 41.800 | Andrew Guy, CFA | World's leading generic drug manufacturer. Buying Barr Laboratories, which will broaden its product range and increase its strength. Generic drugs are a solution to a lot of the problems that are facing the global health industry. | 2008-11-19 | |
| TOP PICK | 42.980 | Norman Levine | Largest generic drug company in the world. Company outlook was better than what the Street was looking for. People are moving more towards generics as economies weaken. (Recommends you do partial buys on a gradual basis.) | 2008-11-11 | |
| PAST TOP PICK | 41.410 | Norman Levine | (Top Pick Oct 23/07, Down 4%). World’s largest generic drug manufacturer; owns some brand name drugs, picks up drugs when they go off patent. Combine with owning a brand name drug company in portfolio. It’s a buy today. 3-5 years down the road, growth is in drugs coming off patent. | 2008-10-14 | |
| TOP PICK | 41.410 | Andrew Guy, CFA | Biggest Generic Drug manufacturer, getting into Japan where only a small percentage is generic. Strong cash flow. | 2008-10-14 | |
| PAST TOP PICK | 47.560 | Norman Levine | (A Top Pick Sept 11/07. Up 12%.) Generics are the best place to be in pharmaceuticals. This is the largest, the leader and the fastest growing. Has the best products coming on. Have made some great acquisitions. | 2008-09-05 | |
| Comment | 47.070 | David Baskin | An interesting stock as this is one of the best generic drug manufacturers. Increasingly, as the blockbuster drugs do come off patent, there is probably more upside with the generics. Not a fan of pharmaceuticals because of the potential for litigation. | 2008-09-02 | |
| Comment | 45.770 | Duncan Stewart | Global pharmaceutical. In a trading range for almost a year. Not a particularly high R & D industry. A lot of generics. It might add a lot of stability to a portfolio. Prefers Johnson & Johnson (JNJ-N). | 2008-07-28 | |
| TOP PICK | 44.090 | Andrew Guy, CFA | Leading by far the number of potential drugs that they can manufacture. Very well tied in to the Israeli technology sector. Have the first drug that shows a reduced effect of Parkinson's. | 2008-07-22 | |
| TOP PICK | 43.700 | Norman Levine | Largest generic drug manufacturer globally. Acquiring Barr Labs (BRL-N) giving them more international exposure. Also have some proprietary drugs, most importantly a Parkinson drug. | 2008-07-21 | |
| TOP PICK | 44.810 | Norman Levine | Largest generic drug company in the world. Have the leading drug for multiple sclerosis that is going to be produced generically by competition but will take 3 or 4 years. Just announced 3rd stage of a drug for Parkinson’s that is the only one that has slowed and possibly stopped the progression of Parkinson's. Has many years of patent protection. | 2008-06-24 | |
| BUY | 44.710 | Norman Levine | (Market Call Minute.) Biggest generic drug manufacturer in the world. More and more drugs are coming off patent so the growth outlook is fabulous. | 2008-05-12 | |
| DON'T BUY | 46.250 | Pat Naccarato | Beneficiaries of the branded drug companies’ losses are generic manufacturers. This one is the largest. Not sure if the timing is exactly appropriate right now, but on a longer-term perspective, this should benefit with generic drug manufacturing. | 2008-04-07 | |
| TOP PICK | 49.650 | Norman Levine | This pharmaceutical is in the sweet spot. The world's largest generic drug company. Also have proprietary drugs that it has developed on its own. They have been the main beneficiary of the switch from big name patented drugs to off-patent drugs. Have about 18% of the US generics and are working towards 30% through acquisitions and generics as drugs go off patent. 1% dividend only, because it is a growth company. The stock has a long way to go. | 2008-02-26 | |
| BUY | 46.900 | Norman Levine | Largest generic drug manufacturer globally. Had a bit of a correction when the head of its North American operations resigned and was replaced. He has a 2-pronged approach to the drug industry. This is his growth generic company and he owns Pfizer (PFE-N) as his value dividend play. | 2008-02-11 | |
| PAST TOP PICK | 47.910 | Norman Levine | (A Top Pick Jan 9/07. Up 45,7%.) World’s largest generic drug manufacturer. Has been a major beneficiary of the majors losing patents. Still buying. | 2008-01-07 | |
| TOP PICK | 44.200 | Norman Levine | A long time favourite. It is the largest generic pharmaceutical company. They will be able to benefit from the aging population and government wanting more generic prescriptions. He bought this stock in the low 30's. | 2007-10-23 | |
| BUY | 44.813 | Norman Levine | The best company to own in the generics drug area. | 2007-10-02 | |
| TOP PICK | 43.350 | Norman Levine | Sitting by its all-time high even in this poor market. Largest generic drug manufacturer in the world. A major beneficiary of an economic slowdown because people will switch from branded products to generics. Major beneficiary of drugs coming off patent. | 2007-09-11 | |
|
| |||||
| PAST TOP PICK | 43.970 | Norman Levine | (A Top Pick July 25/06. Up 42%.) Still a Buy. The biggest generic drug manufacturer in the world. | 2007-07-18 | |
| BUY | 36.550 | Paul Harris, CFA | An Israeli generics pharmaceutical company. At these levels, it is a very interesting stock. | 2007-03-16 | |
| TOP PICK | 32.820 | Norman Levine | World's largest generic drug manufacturer. Has gone from being a growth stock to a value stock. A lot more patented drugs will be coming off in 2007 and 2008. | 2007-01-09 | |
| BUY | 31.650 | Norman Levine | World’s largest generic drug manufacturer. Also have their own branded drug division. Made some acquisitions and is going through some digestion, but a year from now the stock should be significantly higher. | 2006-12-20 | |
| BUY | 31.860 | Paul Harris, CFA | Generic pharmaceutical company. Very well run. Lots of cash. | 2006-12-12 | |
| BUY | 32.510 | Norman Levine | World’s largest generic drug manufacturer. A value stock. Has a great pipeline of new drugs coming out in the next few years, both generic and its own proprietary drugs. Pfizer’s (PFE-N) Lipitor drug does not come off patent until 2011. | 2006-12-05 | |
| BUY | 30.700 | Norman Levine | World’s largest generic drug manufacturer with most sales in North America. Reported great earnings, but stock has acted poorly lately because next year’s growth is not going to be as big. Good price. | 2006-11-14 | |
| BUY | 34.630 | Paul Harris, CFA | Generic drugs. Trades and about 16 X earnings. Has a lot of cash on its balance sheet. There is a lot of competition in the generic sector still expects there will be mergers. It should continue to do well. | 2006-08-22 | |
| TOP PICK | 30.850 | Norman Levine | World's largest generic drug manufacturer. Gone from being a growth stock to a value stock. Merck and Pfizer have come out with their own generics when their drugs came off patent. Based in Israel. The drop in price gives a good opportunity. | 2006-07-25 | |
| BUY | 32.081 | Norman Levine | Largest generic drug manufacturer in the world. Likes long-term outlook for generics. Emerging markets have come off which affected the stock. Bit of a tumult on drugs coming off patent with original patent owners issuing drugs for less than generics. A temporary phenomena and this company will again be on top. | 2006-07-11 | |
| WAIT | 32.300 | Peter Hofstra | In the top 2 of the world's generic drug manufacturers. Interesting dynamics going on in the healthcare sector. When the patent came off Zocor, Merck (MRK-N) lowered their price below the generic price. This was a first but other companies could follow this tactic so, he is staying on the sidelines. Recently sold his holdings. | 2006-07-10 | |
| PAST TOP PICK | 35.670 | Neil Wickham | (A Top Pick May 30/05. Up 4%.) Trading at a lower multiple and is a bigger stronger company than it was a year ago. Has more new business going for them. Still attractive. | 2006-06-20 | |
| BUY | 37.070 | Norman Levine | Israeli based pharmaceutical company. Largest generic drug manufacturer in the world. Most recent quarter was a little lighter than expected. Acquired a US company made the numbers are little bit light. Good opportunity to buy. | 2006-05-30 | |
| BUY | 40.920 | Norman Levine | The largest generic pharmaceutical company in the world. Feels the future in pharmaceuticals is in generics. A good buying opportunity. | 2006-04-27 | |
| HOLD | 39.730 | David Burrows | Over the last few years, has done a lot better than the industry. One of the largest generic drugs. Pharmaceutical sector has really gone to sleep. | 2006-04-10 | |
| WAIT | 42.100 | David Driscoll | It's getting to have a lot of compition in that space. It's had a wonderful run, but it's getting rich. I would wait maybe a year or two. The sector overall. | 2006-02-23 | |
| BUY | 40.630 | Norman Levine | Has been the best performing drug stock for quite awhile so it is natural that there should be some profit-taking. Just in the process of completing another acquisition. Once that is finished, the stock should come back. Still has a lot of upside. | 2006-01-25 | |
| PAST TOP PICK | 43.510 | Norman Levine | (A Top Pick Oct 25/05. Up 14%.) The world's largest generic drug manufacturer. In the process of finalising a major acquisition. This is his growth drug stock and uses Pfizer (PFE-N) as his value drug stock. Still likes. | 2005-12-28 | |
| BUY | 43.720 | Norman Levine | A growth pharmaceutical. With its latest purchase, it will be the largest generic drug manufacturer in the world. It also develops its own drugs. Has a phenomenal record. Has great growth ahead of them. | 2005-12-13 | |
| BUY | 41.890 | Norman Levine | An Israeli based generic drug manufacturer, the largest in the world. Still likes it very much. | 2005-12-05 | |
|
| |||||
| TOP PICK | 40.120 | David Burrows | Likes sectors that are out of favour and are underowned and finding companies that are flourishing despite a difficult environment. This one is a multinational, multi-billion dollar manufacturer, developer and marketer of mostly generic, but some brand name drugs. Have about 140 products in the pipeline waiting approval. Good growth rate. | 2005-11-11 |
